Inve India ▾

Alkem Lab share price & results

Alkem Lab· Healthcare

Results to
Jun 2026
Latest analysed call
Q1 FY27
Ownership as of
Sept 2026

Indian pharma major making branded generics, APIs, biosimilars and medical devices, sold across 40+ countries.

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue3,740 ₹ crore+10.9% YoYQuarterly, as filedQuarter to Jun 2026Revenue from operations as filed.
Operating margin20.0 %−2.0 pts YoYOperating profit / revenueQuarter to Jun 2026For the quarter; a change is in percentage points.
Net profit521 ₹ crore−22.0% YoYQuarterly, as filedQuarter to Jun 2026Profit after tax as filed.
Return on equity17.61 %−0.5 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin10.03 %+0.2 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)13.36 %+11.1 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Revenue change against the same period one year earlier.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Jun 2026

Guidance

What management said, and what became of it

5 of 8 judged targets kept · 15 open · verdicts reflect calls analysed to Q1 FY27.

Alkem Lab management guidance track record on Inve: 23 targets tracked across analysed earnings calls (5 achieved, 3 missed, 15 open).

TargetOriginal wordingSaidLatest callVerdict
Occlutech Acquisition Closurewithin 45 to 60 days from May 28, 2026
Call transcript, Q4 FY26 · 28 May 2026		Q4 FY26Q1 FY27:Acquisition closed in mid-July 2026, within the guided 45-60 day timeline.
Call transcript, Q1 FY27 · 20 Aug 2026		Achieved
Tolvaptan US LaunchSeptember or October 2026
Call transcript, Q4 FY26 · 28 May 2026		Q4 FY26Q1 FY27:No update provided on the launch timeline, with the target window of Sep/Oct 2026 approaching.
Call transcript, Q1 FY27 · 20 Aug 2026		Ghosted
Effective Tax Rate FY2727% to 29%
Call transcript, Q4 FY26 · 28 May 2026		Q4 FY26Q1 FY27:Guidance revised upwards to 30-32% at a consolidated level due to losses in subsidiaries where DTA is not recognized.
Call transcript, Q1 FY27 · 20 Aug 2026		Revised Down

Source: Inve Guidance Tracker for Alkem Lab · to Q1 FY27

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

3 of Alkem Lab's 23 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 20 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Price

₹5,078 +0.95% · +₹48

Last close 27 Oct 2026 · NSE · INR · Source: Inve

Performance −8.4% 1Y

₹5.0k₹5.2k₹5.4k₹5.6k₹5.8kOct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26Q2 FY26 — 13 Nov 2025Q3 FY26 — 13 Feb 2026Q4 FY26 — 27 May 2026Q1 FY27 — 20 Aug 2026

1Y: ₹5,545 on 24 Oct 2025 → ₹5,078. High ₹5,890 (11 Feb 2026), low ₹4,947 (23 Oct 2026).

Previous close
₹5,030
Market cap
₹60.4k Cr
52-week range
₹4,947 – ₹5,890
One year
−7.26%
Price to earnings (TTM to Jun 2026)
26.58×
Return on equity (TTM to Jun 2026)
17.61%

Overview

Symbol
NSE:ALKEM
Exchange
NSE
Currency
INR

What Alkem Lab does

Based on the company's own presentations, annual report and earnings calls.

Alkem Laboratories is one of India's top-five pharmaceutical companies, operating across the value chain in branded generics, complex generics, biosimilars, APIs and nutraceuticals, with leadership positions in therapy areas such as anti-infectives, gastrointestinal, pain management and vitamins/minerals/nutrients. It earns primarily by manufacturing and selling formulations to doctors, hospitals, stockists and pharmacies in India (through a large field force) and via international subsidiaries such as Ascend Labs in the US, Australia, Latin America and Europe. Biosimilars are developed and manufactured through its subsidiary Enzene Biosciences, and in FY2025 the company entered the medical-devices business through Alkem MedTech, acquiring an orthopaedic-implants manufacturing facility and licensing premium implant technology.

Segments

  • Domestic Pharma
  • International Subsidiaries
  • API
  • Biosimilars
  • Wellness
  • MedTech
Countries with commercial presence
40+
Manufacturing facilities (incl. 6 USFDA-approved)
18
R&D centres
3
Medical representatives (field force)
12,500+
Brands
800+
SKUs
1,500+
Founded 1973Employees 21,000 (FY2024-25 (31 Mar 2025)) Company website

How the price took the results

close before → close after

Q1 FY27
+0.3%
20 Aug
Q4 FY26
+0.9%
28 May
Q3 FY26
−8.0%
13 Feb
Q2 FY26
−0.7%
13 Nov

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Your own record

Start an Inve Case for Alkem Lab

Free account: one company. Everything above stays public.

Write why you follow Alkem Lab and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Healthcare companies

All Healthcare companies → · Healthcare earnings growth →

Learn to analyse Alkem Lab

Guides on how to read this kind of business and the numbers that matter.